continu
middl
east
respiratori
syndrom
mer
threat
highlight
import
develop
effect
antivir
therapeut
prevent
treat
mer
coronaviru
merscov
infect
surfac
spike
protein
guid
merscov
entri
host
cell
bind
cellular
receptor
dipeptidyl
follow
fusion
viru
host
cell
membran
merscov
protein
repres
key
target
develop
therapeut
block
viral
entri
inhibit
membran
fusion
area
coveredthi
review
illustr
merscov
protein
structur
function
particularli
receptorbind
domain
rbd
heptad
repeat
therapeut
target
summar
current
advanc
develop
antimerscov
therapeut
focus
neutral
monoclon
antibodi
mab
antivir
peptid
expert
opinionno
antimerscov
therapeut
approv
human
use
sever
starget
neutral
mab
peptid
demonstr
efficaci
merscov
infect
provid
feasibl
develop
gener
human
neutral
mab
target
rbd
potent
target
region
protein
howev
emerg
escap
mutant
virus
mab
limit
make
necessari
combin
neutral
mab
recogn
differ
neutral
epitop
engin
improv
efficaci
reduc
cost
optim
peptid
sequenc
expect
produc
nextgener
antimerscov
peptid
improv
potenc
indispens
complementari
role
mediat
membran
fusion
undergo
dramat
conform
chang
prior
membran
fusion
protein
present
nativ
trimer
structur
viral
surfac
membran
fusion
process
dissoci
two
heptad
repeat
region
design
form
bundl
fusion
core
expos
hydrophob
fusion
peptid
insert
host
membran
bring
viral
host
membran
proxim
fusion
figur
understand
fusion
core
structur
guid
ration
design
merscov
fusion
inhibitor
antimerscov
therapeut
specif
target
base
fusion
core
structureth
fusion
core
structur
merscov
similar
sarscov
distinct
coronavirus
mous
hepat
viru
mhv
xray
crystallographi
identifi
stabl
fusion
core
structur
contain
parallel
trimer
coil
coil
three
longer
helic
three
shorter
chain
surround
obliqu
antiparallel
manner
helic
merscov
form
residu
region
residu
region
respect
addit
residu
form
oneturn
helix
cterminu
fusion
protein
interact
helic
predominantli
hydrophob
consist
number
hydrogen
bond
form
key
residu
mainli
locat
around
nand
ctermin
region
helic
base
crystal
structur
merscov
two
peptid
design
span
residu
residu
domain
respect
design
investig
interact
determin
stabil
result
show
interact
form
mixtur
equimolar
concentr
constitut
helic
complex
strong
thermal
stabil
protein
need
activ
entri
target
cell
activ
direct
one
follow
proteas
endosom
cathepsin
bl
proprotein
convertas
depend
host
cell
type
tissu
exampl
cathepsin
l
may
activ
merscov
protein
viral
entri
natur
suscept
cell
addit
use
bioinformat
peptid
cleavag
assay
two
cleavag
site
identifi
furin
proteas
boundari
within
respect
indic
merscov
protein
proteolyz
furin
protein
biosynthesi
cleavag
site
viru
entri
cleavag
site
respect
twostep
furinmedi
proteas
cleavag
protein
suggest
import
furin
activ
merscov
fusion
infect
structur
function
merscov
protein
determin
key
role
protein
import
target
develop
therapeut
mer
specif
target
protein
includ
ntermin
domain
ntd
rbd
region
subunit
subunit
well
target
relat
function
merscov
protein
therapeut
agent
current
develop
base
target
character
antimerscov
neutral
mab
mab
antagonist
peptid
fusion
inhibitor
proteas
inhibitor
sirna
molecul
antimerscov
agent
mainli
block
receptor
bind
membran
fusion
thu
lead
inhibit
merscov
infect
none
antimerscov
therapeut
agent
approv
human
use
proteintarget
antimerscov
therapeut
agent
includ
neutral
mab
peptid
summar
tabl
merscov
outsid
rbd
therapeut
target
merscov
outsid
rbd
may
serv
potenti
target
develop
therapeut
countermeasur
merscov
infect
neutral
mab
identifi
target
region
exampl
mous
mab
recogn
neutral
epitop
outsid
rbd
may
neutral
pseudotyp
merscov
infect
addit
human
mab
recogn
neutral
epitop
residu
also
neutral
infect
pseudotyp
merscov
neutral
mab
specif
outsid
rbd
could
use
supplement
rbdspecif
mab
increas
antimerscov
activ
rbd
major
target
antimerscov
therapeut
merscov
neutral
antibodi
target
rbd
rbdspecif
mab
potent
neutral
activ
target
region
outsid
rbd
region
tabl
suggest
merscov
rbd
could
serv
main
neutral
target
develop
antibodybas
therapeut
rbdtarget
mous
neutral
mabssever
mousederiv
rbdtarget
merscov
neutral
mab
gener
hybridoma
mice
immun
merscov
sencod
dna
rbd
protein
maintain
merscov
neutral
abil
block
receptor
bind
mous
neutral
antibodi
may
inhibit
bind
near
key
rbd
residu
figur
tabl
potent
neutral
infect
diverg
pseudotyp
live
merscov
shown
conformationdepend
neutral
mab
effici
block
merscov
rbd
bind
receptor
solubl
cellassoci
form
bind
epitop
critic
residu
rbd
also
inhibit
smediat
pseudotyp
merscov
entri
cell
potent
neutral
pseudotyp
live
merscov
infect
also
reveal
mous
mab
neutral
merscov
infect
high
effici
interf
interact
compet
rbd
bind
addit
competit
effect
mous
mab
capabl
recogn
variou
rbd
neutral
epitop
may
synergist
effect
neutral
merscov
infect
exampl
mab
recogn
neutral
epitop
near
residu
respect
opposit
side
rbd
differ
profil
neutral
panel
eight
pseudotyp
merscovsbear
protein
unabl
neutral
pseudotyp
merscov
express
protein
strain
contain
mutat
could
neutral
pseudotyp
merscov
irrespect
mutat
nevertheless
protect
therapeut
abil
mous
neutral
mab
human
evalu
appropri
anim
model
notabl
crystal
structur
two
mous
neutral
mab
merscov
rbdbind
complex
avail
neutral
epitop
identifi
rbd
critic
mab
bind
figur
tabl
character
rbdmab
crystal
structur
identifi
neutral
epitop
provid
use
guidanc
human
merscov
mab
base
develop
effect
mabbas
antimerscov
therapeut
agent
neutral
mab
target
merscov
rbd
extens
studi
mab
gener
use
screen
b
cell
deriv
convalesc
patient
nonimmun
human
antibodi
phage
display
librari
human
mous
mab
compet
merscov
rbd
residu
bind
rbdtarget
human
mab
may
effici
block
rbd
bind
receptor
subsequ
viru
entri
target
cell
thu
inhibit
merscov
infect
figur
b
sever
key
residu
critic
mab
bind
includ
identifi
rbd
merscov
figur
b
c
tabl
first
human
neutral
mab
isol
merscovinfect
individu
addit
bind
merscov
mab
also
strongli
bind
rbd
residu
thu
interf
bind
rbd
viral
cellular
receptor
lead
potent
neutral
infect
three
merscov
strain
isol
includ
likewis
mab
inhibit
infect
pseudotyp
live
merscov
block
interact
cell
surfac
prevent
syncytia
format
inhibit
merscov
entri
suscept
cell
andor
mab
effici
neutral
infect
live
merscov
strain
pseudovirus
express
protein
differ
strain
mutat
f
v
f
respect
rbd
similar
mous
neutral
mab
human
neutral
mab
also
demonstr
synergist
effect
prevent
merscov
infect
case
mab
still
neutral
natur
occur
escap
mutant
merscov
gener
differ
antibodi
epitop
group
although
might
neutral
epitop
group
crystal
structur
mabfabmerscov
rbd
complex
avail
two
human
neutral
mab
analys
complex
reveal
two
critic
residu
posit
rbd
import
rbd
recognit
mab
bind
receptor
figur
b
disrupt
proteinprotein
proteincarbohydr
interact
rbd
effect
inhibit
smediat
pseudotyp
merscov
entri
infect
interestingli
note
crystal
structur
complex
epitop
mab
map
rbd
residu
overlap
site
figur
c
indic
recogn
ident
rbd
epitop
thu
explain
potent
neutral
activ
confer
human
neutral
mab
current
sever
rbdspecif
human
neutral
mab
evalu
therapeut
effect
merscovinfect
anim
model
includ
mice
human
mice
mice
well
rabbit
rhesu
monkey
demonstr
protect
abil
merscov
infect
exampl
mab
prophylact
therapeut
protect
mice
infect
two
merscov
strain
also
protect
receptordefici
ifnarko
mice
challeng
virus
addit
mab
block
merscov
infect
diseas
mice
protect
viru
challeng
furthermor
recent
shown
mab
reduc
viral
rna
rabbit
infect
merscov
posttreat
protect
mice
merscov
infect
mab
reduc
lung
patholog
rhesu
monkey
infect
merscov
treatment
identifi
receptor
merscov
therapeut
agent
includ
antibodi
specif
antagonist
block
bind
interact
merscov
rbd
thu
inhibit
merscov
infect
tabl
util
aforement
mechan
antibodi
prevent
merscov
entri
suscept
cell
significantli
block
viru
infect
epitop
mab
appear
map
residu
cover
region
residu
addit
protein
adenosin
deaminas
ada
compet
merscov
rbd
bind
especi
crucial
residu
determin
role
natur
occur
antagonist
merscov
infect
identifi
antimerscov
agent
util
altern
neutral
mab
prevent
merscov
infect
like
sarscov
domain
subunit
merscov
protein
import
target
develop
fusion
inhibitor
merscov
tabl
note
peptid
deriv
subunit
domain
exhibit
good
antimerscov
activ
low
inhibitori
activ
merscov
infect
possibl
peptid
form
solubl
stabl
trimer
tendenc
aggreg
physiolog
solut
pb
inde
indic
peptid
potent
inhibit
merscov
replic
smediat
cellcel
fusion
inhibitori
concentr
ic
respect
peptid
includ
inhibitori
activ
even
high
concentr
studi
demonstr
antivir
activ
peptid
correl
peptid
length
longer
sequenc
better
antivir
activ
shorter
sequenc
may
due
fact
longer
peptid
tend
form
stabl
coiledcoil
structur
peptid
exampl
peptid
maintain
strong
inhibitori
activ
merscov
smediat
cellcel
fusion
ic
respect
short
peptid
exhibit
antimerscov
activ
previou
studi
indic
stabil
solubl
antivir
activ
antihiv
peptid
improv
introduc
charg
residu
peptid
similarli
sitemut
residu
includ
form
intramolecular
saltbridg
introduc
peptid
without
block
interact
merscov
shown
introduct
mutat
peptid
mutat
peptid
significantli
increas
peptid
stabil
water
solubl
enhanc
inhibitori
activ
merscov
smediat
cellcel
fusion
particular
peptid
interact
peptid
form
stabl
complex
block
format
merscov
subsequ
membran
fusion
figur
b
thu
potent
inhibit
infect
proteinexpress
pseudotyp
merscov
without
mutat
residu
studi
confirm
possibl
improv
stabil
solubl
antivir
potenc
peptid
vivo
protect
efficaci
merscov
peptid
evalu
mice
mice
intranas
administr
peptid
viral
challeng
effect
protect
challeng
mice
infect
merscov
without
mutat
evidenc
reduc
viral
load
lung
tissu
decreas
mortal
mice
challeng
lethal
dose
merscov
protect
could
enhanc
combin
peptid
interferon
cytokin
potent
inhibit
merscov
infect
viru
clearanc
viru
challeng
studi
suggest
peptid
nasal
spray
formul
could
appli
protect
highrisk
popul
famili
member
mer
patient
healthcar
worker
other
close
contact
mer
patient
combin
antivir
agent
treatment
mer
patient
discuss
protein
merscov
must
cleav
cellular
proteas
eg
subunit
function
bind
receptor
mediat
membran
fusion
respect
therefor
relat
cellular
proteas
serv
target
develop
inhibitor
proteinmedi
viral
fusion
entri
target
cell
tabl
sinc
endosom
cathepsin
bl
transmembran
serin
proteas
activ
merscov
smediat
viruscel
entri
uptak
treatment
cell
cathepsin
bl
inhibitor
teicoplanin
inhibitor
camostat
mesyl
block
merscov
entri
target
cell
demonstr
furin
ubiquit
express
proteas
play
key
role
proteaseactiv
merscov
sbase
fusion
thu
treatment
merscovpermiss
cell
furin
inhibitor
decrvkrcmk
inhibit
merscov
smediat
entri
viru
infect
dosedepend
manner
moreov
sirna
silenc
furin
activ
decreas
merscov
smediat
entri
accordingli
blockag
furin
cleavag
cleavag
site
significantli
reduc
viru
infect
differ
proteas
process
protein
stage
viru
uptak
proprotein
convertas
util
protein
substrat
process
dispens
activ
protein
therefor
blockad
proteas
affect
proteindriven
cellcel
viruscel
fusion
merscov
infect
although
reduc
process
protein
infect
cell
therefor
advis
host
cell
proteasetarget
antimerscov
agent
focus
enzym
process
protein
viru
uptak
stage
region
merscov
protein
identifi
serv
supplement
target
antimerscov
therapeut
instanc
mous
mab
demonstr
bind
merscov
subunit
neutral
infect
pseudotyp
merscov
bear
protein
low
neutral
activ
tabl
specif
epitop
clearli
defin
studi
also
found
interferoninduc
transmembran
protein
ifitm
may
inhibit
entri
smediat
merscov
ifitmtransduc
cell
tabl
howev
inhibit
activ
merscov
less
effici
observ
human
coronavirus
continu
increas
mer
case
coupl
continu
mer
outbreak
result
zoonot
sourc
possibl
humantohuman
transmiss
merscov
highlight
import
develop
effect
antivir
agent
control
mer
note
structur
function
merscov
protein
viru
entri
viruscel
membran
fusion
effect
determin
crucial
role
protein
import
therapeut
target
inde
varieti
neutral
mab
therapeut
agent
alreadi
develop
base
viral
protein
demonstr
protect
efficaci
merscov
infect
although
none
current
approv
applic
human
summari
avail
preclin
therapeut
guid
develop
effect
antimerscov
therapeut
agent
human
use
merscov
protein
key
target
develop
therapeut
merscov
infect
sinc
emerg
mer
number
starget
antimerscov
therapeut
agent
includ
mous
human
neutral
mab
antimerscov
peptid
identifi
vitro
efficaci
cell
cultur
andor
vivo
efficaci
anim
model
provid
feasibl
develop
addit
avail
crystal
structur
mabrbd
complex
complex
applic
elucid
mechan
action
starget
antimerscov
neutral
mab
peptid
thu
help
engin
new
neutral
antibodi
design
novel
peptid
improv
protect
efficaci
merscov
infect
notwithstand
high
potenc
mous
neutral
mab
vitro
test
human
appropri
direct
use
human
due
potenti
risk
humananti
mous
antibodi
respons
side
effect
nevertheless
neutral
epitop
identifi
mous
neutral
mab
guid
design
human
merscov
mab
develop
effect
antivir
therapeut
vaccin
merscov
remark
human
neutral
mab
shown
efficaci
protect
merscov
infect
sever
anim
model
demonstr
high
potenti
develop
effect
prophylact
therapeut
agent
human
use
sinc
intraven
iv
intraperiton
ip
inject
merscov
srbdtarget
human
human
neutral
mab
confer
complet
protect
anim
merscov
infect
without
caus
side
effect
patholog
thu
suggest
rout
select
deliv
antimerscov
mab
merscovinfect
patient
compar
human
neutral
mab
target
region
merscov
protein
target
rbd
potent
could
recogn
key
residu
respons
bind
note
chang
one
sever
critic
residu
rbd
may
lead
gener
escap
mutant
viru
strain
neutral
mab
target
origin
residu
rbd
reduc
lose
neutral
activ
new
strain
phenomenon
elucid
need
combin
applic
two
potent
human
neutral
mab
target
differ
neutral
epitop
rbd
function
region
merscov
protein
differ
mechan
action
order
improv
antivir
activ
diverg
viru
strain
includ
escap
mutant
strain
attent
also
paid
challeng
develop
therapeut
mab
poor
tissu
penetr
result
larg
molecular
size
high
product
cost
inadequ
pharmacokinet
challeng
make
necessari
use
antibodi
engin
technolog
gener
merscov
starget
antibodi
fragment
smaller
molecul
weight
reduc
product
cost
good
tissu
penetr
maintain
suffici
protect
efficaci
similar
antihiv
peptid
stabil
solubl
antivir
activ
merscov
sspecif
peptid
improv
introduc
intramolecular
saltbridg
increas
peptid
length
therefor
optim
peptid
expect
produc
nextgener
antimerscov
peptid
improv
inhibitori
efficaci
altern
promis
approach
combin
hritarget
peptid
inhibitor
rbdspecif
neutral
mab
may
result
synergist
antivir
effect
diverg
merscov
strain
includ
resist
starget
neutral
mab
peptid
view
key
role
merscov
protein
viru
infect
abil
protein
serv
import
target
expect
effect
safer
mer
van
merscov
bind
dipeptidyl
peptidas
via
receptorbind
domain
rbd
spike
protein
subunit
mediat
viru
entri
target
cell
via
subunit
therefor
protein
play
pivot
role
merscov
infect
serv
import
therapeut
target
specif
therapeut
target
protein
includ
ntermin
domain
rbd
heptad
repeat
major
target
develop
antimerscov
therapeut
monoclon
antibodi
mab
peptid
fusion
inhibitor
respect
rbdtarget
neutral
mab
block
receptor
bind
key
residu
lead
inhibit
merscov
infect
sever
rbdspecif
human
neutral
mab
demonstr
therapeut
efficaci
merscov
infect
transduc
human
mice
rabbit
rhesu
monkey
peptid
inhibit
merscov
infect
block
form
bundl
structur
prevent
merscov
challeng
mice
need
combin
mab
recogn
differ
neutral
epitop
improv
efficaci
escap
mutant
merscov
strain
engin
reduc
cost
good
tissu
penetr
feasibl
optim
peptid
improv
inhibitori
efficaci
combin
neutral
mab
enhanc
antimerscov
therapeut
efficaci
box
summar
key
point
contain
articl
schemat
diagram
merscov
protein
membran
fusion
merscov
starget
mab
peptid
schemat
diagram
merscov
membran
fusion
follow
major
process
involv
merscov
membran
fusion
receptor
bind
stage
protein
exist
trimer
bind
cellular
receptor
via
bind
trigger
conform
chang
protein
lead
dissoci
expos
thu
enter
intermedi
prehairpin
stage
fusion
hairpin
stage
helic
associ
form
bundl
fusion
core
bring
membran
viru
cell
close
proxim
fusion
b
schemat
diagram
mechan
action
merscov
neutral
mab
peptid
rbdspecif
antibodi
igg
fab
bind
viral
interrupt
bind
rbd
thu
block
viru
infect
peptid
eg
bind
form
heterolog
thu
interfer
subsequ
fusion
core
format
viruscel
membran
fusion
result
inhibit
merscov
infect
tabl
summari
merscov
proteintarget
neutral
mab
vivo
protect
